webinar register page

Webinar banner
Ask the Doctor: Cell-based, Genetic & Immunotherapies in PD
Current treatment of PD relies heavily on replacing lost dopamine either with its precursor L-dopa or dopamine agonists. Though very effective in controlling motor symptoms of PD, long term use of L-dopa is associated with motor fluctuations and dyskinesias. Further, these medications do not control non motor symptoms and also fail to improve some motor symptoms like falls and freezing.

Join us on May 17 at 7PM Central as we interview Dr. Anthony Lang, one of the most highly cited investigators in the field of Movement Disorders, on cell-based, genetic and immune therapy options for Parkinson's.

WHAT ARE CELL-BASED, GENETIC & IMMUNOTHERAPIES?
-Cell-based therapy can be defined as a class of therapy consisting of implantation of cells rich in dopamine that could replace dopamine neurons which have degenerated in PD and can restore dopamine function in a more physiologic manner as compared to oral replacement therapies.

-Genetic therapy is a rapidly evolving, genome editing technology aiming to treat a disease by genetically modifying populations of cells that are either directly functionally impaired or capable of relieving disease symptoms. Gene therapy clinical trials in PD have focused on 4 main targeted approaches: (1) restoring dopamine synthesis, (2) neuroprotection, (3) genetic neuromodulation and (4) addressing disease-specific pathogenic variants.

-Immunotherapy involves targeting the spread, production, aggregation, and degradation of α-syn (alpha-synuclein, a key protein involved in PD pathology).

We will be discussing options for all of the above during our webinar. Attendees are encouraged to submit their questions with registration, but you can also submit your questions live during the webinar. See you soon!

May 17, 2022 07:00 PM in Central Time (US and Canada)

Webinar logo
Webinar is over, you cannot register now. If you have any questions, please contact Webinar host: Skypass Foundation.